Exabis Library
Welcome to the e-CCO Library!
P0660: Comparative Accuracy and Reliability of Handheld versus Cart-Based Ultrasound in assessing Inflammatory Bowel Disease Activity
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0661: Effectiveness of upadacitinib for induction of remission in moderate-to-severe ulcerative colitis: real-world clinical outcomes appear independent of prior tofacitinib exposure
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0662: Comparative effectiveness and safety of upadacitinibx7x7x7 tofacitinibx7x7x7 and filgotinib in patients with Ulcerative Colitis: analysis of whole and propensity score-matched data
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0663: Efficacy and safety of risankizumab therapy in Chinese patients with moderately to severely active crohn’s disease
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0664: Effectiveness and safety of upadacitinib in ulcerative colitis in clinical practice: results from the U-REAL-UC study from ENEIDA
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0665: Long-term efficacy and dose intensification of ustekinumab in achieving clinicalx7x7x7 laboratoryx7x7x7 and endoscopic remission in Crohn’s disease.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0666: Early symptom improvements predict later clinical response and remission at week 12 for patients with ulcerative colitis treated with mirikizumab in the LUCENT-1 study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0667: Therapeutic Optimization of Biologic Therapy in Ulcerative Colitis: A Retrospective Analysis of Endoscopic and Biomarker Outcomes
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0668: Is there a @@Weekend Effect@@ on clinical outcomes in acute severe ulcerative colitis? A single centre retrospective analysis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0669: Safety of intravenous and subcutaneous guselkumab induction administration: Results from the GALAXI and GRAVITI studies in participants with Crohn’s Disease
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P066: CCR2-monocytes are essential for the resolution of inflammation and tissue repair in colitis.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P066: Exploration of critical molecules for optimizing treatment by analyzing inflammatory cytokines in the intestinal mucosa of patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P066: Fibrostenotic phenotype of fibroblasts in Crohn's disease is dependent on tissue stiffness and reversed by LOX inhibition
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P066: Lower serum concentration of sulfated bile acids is associated with Primary Sclerosing Cholangitis Inflammatory Bowel Disease comorbidity and advanced liver fibrosis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P066: ON104, a novel bioengineered antibody targeting oxidized Macrophage Migration Inhibitory Factor (oxMIF) shows efficacy in two distinct models of experimental colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P066: Pharmacologic inhibition of integrin αvβ6 causes tumour shrinkage in colitis associated mouse colon tumours
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P066: Validation of assay for detection of free soluble mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in human serum and cerebrospinal fluid
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P067 Proteins citrullination and Crohn’s disease: PAD4 but not PAD2 is a strong marker of ileal inflammation
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P0670: Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GRAVITI study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0671: Supporting vedolizumab treatment throughout pregnancy: Insights from a population pharmacokinetic model
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM